In TAILOR study [18], patients assigned to the chemotherapy arm (docetaxel) experienced a statistically significant improvement in PFS (2.9 versus 2.4 months; HR, 0.71; 95% CI, 0.53–0.92; P = 0.02) and OS (8.2 versus 5.4 months; HR, 0.73; 95% CI, 0.53–1.00; P = 0.05) compared with erlotinib in second-line therapy for patients with advanced wild-type EGFR NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.